290 related articles for article (PubMed ID: 28007570)
61. Two mouse models carrying truncating mutations in Magel2 show distinct phenotypes.
Ieda D; Negishi Y; Miyamoto T; Johmura Y; Kumamoto N; Kato K; Miyoshi I; Nakanishi M; Ugawa S; Oishi H; Saitoh S
PLoS One; 2020; 15(8):e0237814. PubMed ID: 32804975
[TBL] [Abstract][Full Text] [Related]
62. Oleoylethanolamide: A novel pharmaceutical agent in the management of obesity-an updated review.
Laleh P; Yaser K; Alireza O
J Cell Physiol; 2019 Jun; 234(6):7893-7902. PubMed ID: 30537148
[TBL] [Abstract][Full Text] [Related]
63. Biological functions and metabolism of oleoylethanolamide.
Thabuis C; Tissot-Favre D; Bezelgues JB; Martin JC; Cruz-Hernandez C; Dionisi F; Destaillats F
Lipids; 2008 Oct; 43(10):887-94. PubMed ID: 18704536
[TBL] [Abstract][Full Text] [Related]
64. Oleoylethanolamide differentially regulates glycerolipid synthesis and lipoprotein secretion in intestine and liver.
Pan X; Schwartz GJ; Hussain MM
J Lipid Res; 2018 Dec; 59(12):2349-2359. PubMed ID: 30369486
[TBL] [Abstract][Full Text] [Related]
65. Neural mechanisms underlying hyperphagia in Prader-Willi syndrome.
Holsen LM; Zarcone JR; Brooks WM; Butler MG; Thompson TI; Ahluwalia JS; Nollen NL; Savage CR
Obesity (Silver Spring); 2006 Jun; 14(6):1028-37. PubMed ID: 16861608
[TBL] [Abstract][Full Text] [Related]
66. Hedonic eating in Prader-Willi syndrome is associated with blunted PYY secretion.
Rigamonti AE; Bini S; Piscitelli F; Lauritano A; Di Marzo V; Vanetti C; Agosti F; De Col A; Lucchetti E; Grugni G; Sartorio A
Food Nutr Res; 2017; 61(1):1297553. PubMed ID: 28659728
[TBL] [Abstract][Full Text] [Related]
67. Analysis of gene expression pattern reveals potential targets of dietary oleoylethanolamide in reducing body fat gain in C3H mice.
Thabuis C; Destaillats F; Landrier JF; Tissot-Favre D; Martin JC
J Nutr Biochem; 2010 Oct; 21(10):922-8. PubMed ID: 19954948
[TBL] [Abstract][Full Text] [Related]
68. Oleoylethanolamide: A fat ally in the fight against obesity.
Brown JD; Karimian Azari E; Ayala JE
Physiol Behav; 2017 Jul; 176():50-58. PubMed ID: 28254531
[TBL] [Abstract][Full Text] [Related]
69. Histamine-deficient mice do not respond to the antidepressant-like effects of oleoylethanolamide.
Costa A; Cristiano C; Cassano T; Gallelli CA; Gaetani S; Ghelardini C; Blandina P; Calignano A; Passani MB; Provensi G
Neuropharmacology; 2018 Jun; 135():234-241. PubMed ID: 29596898
[TBL] [Abstract][Full Text] [Related]
70. High circulating ghrelin: a potential cause for hyperphagia and obesity in prader-willi syndrome.
DelParigi A; Tschöp M; Heiman ML; Salbe AD; Vozarova B; Sell SM; Bunt JC; Tataranni PA
J Clin Endocrinol Metab; 2002 Dec; 87(12):5461-4. PubMed ID: 12466337
[TBL] [Abstract][Full Text] [Related]
71. Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3'-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation.
Fegley D; Gaetani S; Duranti A; Tontini A; Mor M; Tarzia G; Piomelli D
J Pharmacol Exp Ther; 2005 Apr; 313(1):352-8. PubMed ID: 15579492
[TBL] [Abstract][Full Text] [Related]
72.
Choi Y; Min HY; Hwang J; Jo YH
Life Sci Alliance; 2022 Nov; 5(11):. PubMed ID: 36007929
[TBL] [Abstract][Full Text] [Related]
73. Oleoylethanolamide Increases Glycogen Synthesis and Inhibits Hepatic Gluconeogenesis via the LKB1/AMPK Pathway in Type 2 Diabetic Model.
Ren T; Ma A; Zhuo R; Zhang H; Peng L; Jin X; Yao E; Yang L
J Pharmacol Exp Ther; 2020 Apr; 373(1):81-91. PubMed ID: 32024803
[TBL] [Abstract][Full Text] [Related]
74. Dietary oleic acid contributes to the regulation of food intake through the synthesis of intestinal oleoylethanolamide.
Igarashi M; Iwasa K; Hayakawa T; Tsuduki T; Kimura I; Maruyama K; Yoshikawa K
Front Endocrinol (Lausanne); 2022; 13():1056116. PubMed ID: 36733808
[TBL] [Abstract][Full Text] [Related]
75. Oleoylethanolamide alleviates macrophage formation via AMPK/PPARα/STAT3 pathway.
Zhao Y; Yan L; Peng L; Huang X; Zhang G; Chen B; Ren J; Zhou Y; Yang L; Peng L; Jin X; Wang Y
Pharmacol Rep; 2018 Dec; 70(6):1185-1194. PubMed ID: 30336422
[TBL] [Abstract][Full Text] [Related]
76. Diet-Induced Obesity Disrupts Histamine-Dependent Oleoylethanolamide Signaling in the Mouse Liver.
Lin L; Mabou Tagne A; Squire EN; Lee HL; Fotio Y; Ramirez J; Zheng M; Torrens A; Ahmed F; Ramos R; Plikus MV; Piomelli D
Pharmacology; 2022; 107(7-8):423-432. PubMed ID: 35691287
[TBL] [Abstract][Full Text] [Related]
77. "To brain or not to brain": evaluating the possible direct effects of the satiety factor oleoylethanolamide in the central nervous system.
Romano A; Friuli M; Eramo B; Gallelli CA; Koczwara JB; Azari EK; Paquot A; Arnold M; Langhans W; Muccioli GG; Lutz TA; Gaetani S
Front Endocrinol (Lausanne); 2023; 14():1158287. PubMed ID: 37234803
[TBL] [Abstract][Full Text] [Related]
78. Children with Prader-Willi syndrome exhibit more evident meal-induced responses in plasma ghrelin and peptide YY levels than obese and lean children.
Bizzarri C; Rigamonti AE; Luce A; Cappa M; Cella SG; Berini J; Sartorio A; Müller EE; Salvatoni A
Eur J Endocrinol; 2010 Mar; 162(3):499-505. PubMed ID: 20019130
[TBL] [Abstract][Full Text] [Related]
79. mTOR and autophagy pathways are dysregulated in murine and human models of Schaaf-Yang syndrome.
Crutcher E; Pal R; Naini F; Zhang P; Laugsch M; Kim J; Bajic A; Schaaf CP
Sci Rep; 2019 Nov; 9(1):15935. PubMed ID: 31685878
[TBL] [Abstract][Full Text] [Related]
80. Colocalization of Oxtr with Prader-Willi syndrome transcripts in the trigeminal ganglion of neonatal mice.
Vaidyanathan R; Schaller F; Muscatelli F; Hammock EAD
Hum Mol Genet; 2020 Jul; 29(12):2065-2075. PubMed ID: 32420597
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
